Guideline/Drug Updates and Errata
RxPrep content (e.g., NAPLEX® Course Book, MPJE®/CPJE Manuals and QBanks) is up-to-date at the time of publishing, but drug information and laws can change at any time. If information changes after a product is published, we will post exam-relevant updates in the Guideline/Drug Updates tables below. If we find anything that needs a correction or clarification, it will be included in the Errata tables below.
Updates: 2024 UWorld RxPrep Course Book
NAPLEX-relevant guideline and drug updates from June 2023 – May 2024
Page | Update Type | Description | ||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chapter 15: Compounding I | ||||||||||||||||||||||||||||||||||||||||
p. 227, 231, 237 | Guideline Update |
Revised United States Pharmacopeia (USP) chapters 795 (Non-sterile Preparations) and 797 (Sterile Preparations) became official on November 1, 2023. The updates most relevant for testing that impact this chapter include: p. 227: Non-Sterile Compounding
p. 231: Sterile Compounding for Emergencies and Segregated Compounding Area
p. 237: Compounding Staff Training
|
||||||||||||||||||||||||||||||||||||||
Chapter 17: Compounding III | ||||||||||||||||||||||||||||||||||||||||
p. 266, 273, 277-278 | Guideline Update |
Revised USP chapters 795 and 797 became official on November 1, 2023. Key updates that impact this chapter include: p. 273: Selecting the Beyond-Use Date for Non-Sterile Preparations
p. 277: Sterile Preparation and Risk
p. 278: Determining the Beyond-Use Date Based on CSP Risk Level
|
||||||||||||||||||||||||||||||||||||||
Chapter 20: Immunizations | ||||||||||||||||||||||||||||||||||||||||
p. 313, 318 | Guideline Update |
The Advisory Committee on Immunization Practices (ACIP) updated their recommendations for influenza vaccine administration in patients with an egg allergy (of any severity). The requirement to administer select vaccines (i.e., those that are not egg-free) in a medical setting under the supervision of a healthcare provider has been removed. No additional safety precautions are required, although providers should always be prepared for emergent situations with any vaccine administration. |
||||||||||||||||||||||||||||||||||||||
p. 314, 320 | Guideline Update |
The Centers for Disease Control (CDC) released the 2024 Immunization Schedules for Children and Adolescents and Adults. The updates most relevant for testing that impact this chapter include: p. 314: New respiratory syncytial virus (RSV) vaccine and antibody recommendations for select populations
p. 320: Pneumococcal vaccines
|
||||||||||||||||||||||||||||||||||||||
Chapter 44: Diabetes | ||||||||||||||||||||||||||||||||||||||||
p. 600-601 | Guideline Update |
The 2024 American Diabetes Association (ADA) Standards of Care update was published. There were no significant changes that impacted the 2024 UWorld RxPrep course book content. |
||||||||||||||||||||||||||||||||||||||
Chapter 47: Contraception & Infertility | ||||||||||||||||||||||||||||||||||||||||
p. 652–654 | New Drug | The FDA has approved norgestrel 0.075 mg (Opill) as the first nonprescription (OTC) oral contraceptive. Opill is a progestin-only pill that should be taken once daily at the same time every day. |
Updates: 2025 UWorld RxPrep Course Book
NAPLEX-relevant guideline and drug updates from June 2024 – May 2025
Page | Update Type | Description | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chapter 1: Preparing for the NAPLEX with UWorld RxPrep | ||||||||||||||||
P. 8 | New NAPLEX Content Outline Effective May 1, 2025 |
NABP released a new NAPLEX Content Outline (their blueprint of tested items), which will go into effect on May 1, 2025. Impact for NAPLEX Candidates testing after May 1, 2025:
New NAPLEX Content Domains for 2025:
The basic competencies required to practice as a pharmacist have not changed. Extensive knowledge about medications and their safe use (ie, Domains 1, 2, and 3) is still required. This will represent 90% of the questions on the NAPLEX. Content from Domains 4 and 5 (representing 10% of the scored questions) is included in UWorld RxPrep material in the following chapters and QBanks:
|
||||||||||||||
Chapter 20: Immunizations | ||||||||||||||||
P. 290, 291 & 296 | Pneumococcal Vaccine Updates |
There are two updates related to pneumococcal vaccination:
|
||||||||||||||
P. 294 & 297 | Seasonal Vaccine Update |
Relevant updates from the Centers for Disease Control & Prevention (CDC) for the 2024–2025 respiratory virus season include:
|
||||||||||||||
Chapter 26: Human Immunodeficiency Virus | ||||||||||||||||
P. 382 | Guideline Update |
The single tablet regimen containing dolutegravir/abacavir/lamivudine (Triumeq) is no longer recommended as a preferred initial antiretroviral therapy regimen for treatment-naive patients with HIV. It is an alternative regimen that can be considered for certain clinical scenarios (eg, unable to tolerate a first-line regimen) if pretreatment testing for HLA-B*5701 is negative. |
Updates: 2025 UWorld RxPrep Course Book
NAPLEX-relevant guideline and drug updates from June 2024 – May 2025
Chapter 1: Preparing for the NAPLEX with UWorld RxPrep | ||||||||||||||||
Page P. 8 |
Update Type New NAPLEX Content Outline Effective May 1, 2025 |
|||||||||||||||
NABP released a new NAPLEX Content Outline (their blueprint of tested items), which will go into effect on May 1, 2025. Impact for NAPLEX Candidates testing after May 1, 2025:
New NAPLEX Content Domains for 2025:
The basic competencies required to practice as a pharmacist have not changed. Extensive knowledge about medications and their safe use (ie, Domains 1, 2, and 3) is still required. This will represent 90% of the questions on the NAPLEX. Content from Domains 4 and 5 (representing 10% of the scored questions) is included in UWorld RxPrep material in the following chapters and QBanks:
|
||||||||||||||||
Chapter 20: Immunizations | ||||||||||||||||
Page P. 290, 291 & 296 |
Update Type Pneumococcal Vaccine Updates |
|||||||||||||||
There are two updates related to pneumococcal vaccination:
|
||||||||||||||||
Page P. 294 & 297 |
Update Type Seasonal Vaccine Update |
|||||||||||||||
Relevant updates from the Centers for Disease Control & Prevention (CDC) for the 2024–2025 respiratory virus season include:
|
||||||||||||||||
Chapter 26: Human Immunodeficiency Virus | ||||||||||||||||
Page P. 382 |
Update Type Guideline Update |
|||||||||||||||
The single tablet regimen containing dolutegravir/abacavir/lamivudine (Triumeq) is no longer recommended as a preferred initial antiretroviral therapy regimen for treatment-naive patients with HIV. It is an alternative regimen that can be considered for certain clinical scenarios (eg, unable to tolerate a first-line regimen) if pretreatment testing for HLA-B*5701 is negative. |
Updates: 2024 UWorld RxPrep Course Book
NAPLEX-relevant guideline and drug updates from June 2023 – May 2024
Chapter 15: Compounding I | ||||||||||||||||||||||||||||||||||||||||
Page p. 227, 231, 237 |
Update Type Guideline Update |
|||||||||||||||||||||||||||||||||||||||
Revised United States Pharmacopeia (USP) chapters 795 (Non-sterile Preparations) and 797 (Sterile Preparations) became official on November 1, 2023. The updates most relevant for testing that impact this chapter include: p. 227: Non-Sterile Compounding
p. 231: Sterile Compounding for Emergencies and Segregated Compounding Area
p. 237: Compounding Staff Training
|
||||||||||||||||||||||||||||||||||||||||
Chapter 17: Compounding III | ||||||||||||||||||||||||||||||||||||||||
Page p. 266, 273, 277-278 |
Update Type Guideline Update |
|||||||||||||||||||||||||||||||||||||||
Revised USP chapters 795 and 797 became official on November 1, 2023. Key updates that impact this chapter include: p. 273: Selecting the Beyond-Use Date for Non-Sterile Preparations
p. 277: Sterile Preparation and Risk
p. 278: Determining the Beyond-Use Date Based on CSP Risk Level
|
||||||||||||||||||||||||||||||||||||||||
Chapter 20: Immunizations | ||||||||||||||||||||||||||||||||||||||||
Page p. 313, 318 |
Update Type Guideline Update |
|||||||||||||||||||||||||||||||||||||||
The Advisory Committee on Immunization Practices (ACIP) updated their recommendations for influenza vaccine administration in patients with an egg allergy (of any severity). The requirement to administer select vaccines (i.e., those that are not egg-free) in a medical setting under the supervision of a healthcare provider has been removed. No additional safety precautions are required, although providers should always be prepared for emergent situations with any vaccine administration. |
||||||||||||||||||||||||||||||||||||||||
p. 314, 320 | Guideline Update | |||||||||||||||||||||||||||||||||||||||
The Centers for Disease Control (CDC) released the 2024 Immunization Schedules for Children and Adolescents and Adults. The updates most relevant for testing that impact this chapter include: p. 314: New respiratory syncytial virus (RSV) vaccine and antibody recommendations for select populations
p. 320: Pneumococcal vaccines
|
||||||||||||||||||||||||||||||||||||||||
Chapter 44: Diabetes | ||||||||||||||||||||||||||||||||||||||||
Page p. 600-601 |
Update Type Guideline Update |
|||||||||||||||||||||||||||||||||||||||
The 2024 American Diabetes Association (ADA) Standards of Care update was published. There were no significant changes that impacted the 2024 UWorld RxPrep course book content. | ||||||||||||||||||||||||||||||||||||||||
Chapter 47: Contraception & Infertility | ||||||||||||||||||||||||||||||||||||||||
Page p. 652–654 |
Update Type New Drug |
|||||||||||||||||||||||||||||||||||||||
The FDA has approved norgestrel 0.075 mg (Opill) as the first nonprescription (OTC) oral contraceptive. Opill is a progestin-only pill that should be taken once daily at the same time every day. |
MPJE Updates: 8th Edition MPJE Review Course
MPJE-relevant updates from April 2024 – present
Page | Update Type | Description | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Chapter 8: Controlled Substances Part 3: Prescribing and Dispensing | ||||||||||
p. 152 | Law change Effective October 2024 |
Restrictions for a take-home supply of methadone for opioid use disorder (OUD) have been simplified and are now permissive of larger quantities. Opioid Treatment Programs are allowed to dispense up to a 28-day supply of methadone for unsupervised self-administration (ie, “take-home”) to qualifying patients for treatment of OUD. Medical practitioners are responsible for determining which patients qualify for a take-home supply based on criteria listed in the regulation (eg, absence of known recent diversion activity, regularity of attendance for supervised methadone administration) in addition to other factors that indicate that the benefits of unsupervised doses outweigh the risks.
|
MPJE Updates: 8th Edition MPJE Review Course
MPJE-relevant updates from April 2024 – present
Chapter 8: Controlled Substances Part 3: Prescribing and Dispensing | ||||||||||
Page p. 152 |
Update Type Law change Effective October 2024 |
|||||||||
Restrictions for a take-home supply of methadone for opioid use disorder (OUD) have been simplified and are now permissive of larger quantities. Opioid Treatment Programs are allowed to dispense up to a 28-day supply of methadone for unsupervised self-administration (ie, “take-home”) to qualifying patients for treatment of OUD. Medical practitioners are responsible for determining which patients qualify for a take-home supply based on criteria listed in the regulation (eg, absence of known recent diversion activity, regularity of attendance for supervised methadone administration) in addition to other factors that indicate that the benefits of unsupervised doses outweigh the risks.
|
CPJE Updates: 8th Edition California Law Summary for CPJE
CPJE-relevant updates from June 2023 – present
Page | Update Type | Description | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Chapter 2: Pharmacy Operations | ||||||||||
p. 8 |
Law update Effective July 2024 |
Continuing education (CE) requirements for pharmacist licensure renewal have been updated. Pharmacists who prescribe schedule II controlled substances must complete at least 1 hour of CE every 4 years pertaining to the risk of addiction associated with these medications. |
||||||||
p. 19 |
Law change Effective January 2023 |
Controlled substance inventory reports must be prepared using an exact physical count, not an estimate, for all federal controlled substance schedules (i.e., schedules II–V) that a pharmacy has in stock (both unopened and opened containers). Prior to this law change, an estimated count was permissible for opened containers of schedule III–V controlled substances based on the number of dosage units. |
||||||||
Chapter 3: Pharmacy Practice Part 1: Prescribing and Dispensing | ||||||||||
p. 49-50 | Law update |
The Notice to Consumers poster has been updated. The poster is now titled “Talk to the Expert” and must replace the “Ask Your Pharmacist!” poster. The content of the poster has been updated to caution consumers to “check” for a list of key information regarding their prescription before leaving the pharmacy. The poster continues to notify consumers of their rights as a patient at the pharmacy. The new poster also includes a QR code that links consumers to other language translations of the poster. If the poster is displayed using a video screen, the QR code must still be capable of being read and displayed for sufficient time for consumers to access the code. |
||||||||
p. 57 |
New Law Effective May 2024 |
The California Department of Public Health has issued a statewide standing order for epinephrine which authorizes a CA school, school district, or county office of education to obtain epinephrine auto-injectors for K-12 schools (ie, elementary, middle, junior high, and high schools). The standing order is acceptable at all pharmacies throughout CA to dispense epinephrine auto-injectors. The maximum number of auto-injectors is four per school per calendar year. If used, these can be refilled (which does not count toward the quantity limit). |
||||||||
Chapter 4: Pharmacy Practice Part 2: Furnishing, Administering and Clinical Services | ||||||||||
p. 69 |
New Law Effective September 2023 |
A pharmacist can furnish oral drugs approved or authorized by the FDA for COVID-19 to a patient that has had a positive test for SARS-CoV-2. When furnishing, the pharmacist must:
|
||||||||
p. 74 |
New Drug Effective July 2023 |
The FDA has approved a new over-the-counter (OTC) naloxone product (brand name RiVive) indicated for the emergency treatment of known or suspected opioid overdose. RiVive will be available as a 3-milligram nasal spray. |
||||||||
p. 75 |
Law update Effective September 2024 |
The “naloxone protocol” has been updated to the “opioid antagonist protocol” for the indication of opioid reversal. Important changes include:
|
||||||||
p. 80-81 |
Law change Effective February 2024 |
The law for furnishing HIV pre-exposure prophylaxis (PrEP) has been updated as follows:
|
||||||||
Chapter 7: Controlled Substances Part 3: Prescribing and Dispensing | ||||||||||
p. 132 |
Law change Effective October 2024 |
Restrictions for a take-home supply of methadone for opioid use disorder (OUD) have been simplified and are now permissive of larger quantities. Opioid Treatment Programs are allowed to dispense up to a 28-day supply of methadone for unsupervised self-administration (ie, “take-home”) to qualifying patients for treatment of OUD. Medical practitioners are responsible for determining which patients qualify for a take-home supply based on criteria listed in the regulation (eg, absence of known recent diversion activity, regularity of attendance for supervised methadone administration) in addition to other factors that indicate that the benefits of unsupervised doses outweigh the risks.
|
Chapter 2: Pharmacy Operations | |||||||||
Page p. 8 |
Update Type Law update Effective July 2024 |
||||||||
Continuing education (CE) requirements for pharmacist licensure renewal have been updated. Pharmacists who prescribe schedule II controlled substances must complete at least 1 hour of CE every 4 years pertaining to the risk of addiction associated with these medications. |
|||||||||
Page p. 19 |
Update Type Law change Effective January 2023 |
||||||||
Controlled substance inventory reports must be prepared using an exact physical count, not an estimate, for all federal controlled substance schedules (i.e., schedules II–V) that a pharmacy has in stock (both unopened and opened containers). Prior to this law change, an estimated count was permissible for opened containers of schedule III–V controlled substances based on the number of dosage units. |
|||||||||
Chapter 3: Pharmacy Practice Part 1: Prescribing and Dispensing | |||||||||
Page p. 49-50 |
Update Type Law update |
||||||||
The Notice to Consumers poster has been updated. The poster is now titled “Talk to the Expert” and must replace the “Ask Your Pharmacist!” poster. The content of the poster has been updated to caution consumers to “check” for a list of key information regarding their prescription before leaving the pharmacy. The poster continues to notify consumers of their rights as a patient at the pharmacy. The new poster also includes a QR code that links consumers to other language translations of the poster. If the poster is displayed using a video screen, the QR code must still be capable of being read and displayed for sufficient time for consumers to access the code. |
|||||||||
Chapter 4: Pharmacy Practice Part 2: Furnishing, Administering and Clinical Services | |||||||||
Page p. 69 |
Update Type New Law Effective September 2023 |
||||||||
A pharmacist can furnish oral drugs approved or authorized by the FDA for COVID-19 to a patient that has had a positive test for SARS-CoV-2. When furnishing, the pharmacist must:
|
|||||||||
Page p. 74 |
Update Type New Drug Effective July 2023 |
||||||||
The FDA has approved a new over-the-counter (OTC) naloxone product (brand name RiVive) indicated for the emergency treatment of known or suspected opioid overdose. RiVive will be available as a 3-milligram nasal spray. | |||||||||
Page p. 75 |
Update Type Law update Effective September 2024 |
||||||||
The “naloxone protocol” has been updated to the “opioid antagonist protocol” for the indication of opioid reversal. Important changes include:
|
|||||||||
Page p. 80-81 |
Update Type Law change Effective February 2024 |
||||||||
The law for furnishing HIV pre-exposure prophylaxis (PrEP) has been updated as follows:
|
|||||||||
Chapter 7: Controlled Substances Part 3: Prescribing and Dispensing | |||||||||
Page p. 132 |
Update Type Law change Effective October 2024 |
||||||||
Restrictions for a take-home supply of methadone for opioid use disorder (OUD) have been simplified and are now permissive of larger quantities. Opioid Treatment Programs are allowed to dispense up to a 28-day supply of methadone for unsupervised self-administration (ie, “take-home”) to qualifying patients for treatment of OUD. Medical practitioners are responsible for determining which patients qualify for a take-home supply based on criteria listed in the regulation (eg, absence of known recent diversion activity, regularity of attendance for supervised methadone administration) in addition to other factors that indicate that the benefits of unsupervised doses outweigh the risks.
|
CPJE Errata: 8th Edition California Law Summary for CPJE
Corrections or clarifications for the 8th Edition UWorld RxPrep CPJE manual
Page | Description | |
---|---|---|
Chapter 3: Pharmacy Practice Part 1: Prescribing and Dispensing | ||
p. 32 |
In the Optometrist (OD) row of the table, the right column should read: Must be certified by the Board of Optometry to prescribe drugs. These optometrists will have three letters starting with a T at the end of their license number. Independent authority:
Dependent authority:
|
|
Chapter 7: Controlled Substances Part 3: Prescribing and Dispensing | ||
p. 135 |
The first sentence of the second paragraph below the “Purchase Requirements for OTC Sales” section should read: Although the DEA requires that the logbook be kept in a secure location for at least two years, California law is more strict and requires records to be kept for at least three years. |
Chapter 3: Pharmacy Practice Part 1: Prescribing and Dispensing | ||
Page p. 32 |
||
In the Optometrist (OD) row of the table, the right column should read: Must be certified by the Board of Optometry to prescribe drugs. These optometrists will have three letters starting with a T at the end of their license number. Independent authority:
Dependent authority:
|
||
Chapter 7: Controlled Substances Part 3: Prescribing and Dispensing | ||
p. 135 |
The first sentence of the second paragraph below the “Purchase Requirements for OTC Sales” section should read: Although the DEA requires that the logbook be kept in a secure location for at least two years, California law is more strict and requires records to be kept for at least three years. |